A phase 3 trial found daraxonrasib nearly doubled overall survival in previously treated metastatic pancreatic cancer. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results